Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001475

Piroxicam for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Piroxicam, 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C15H13N3O4S
Numéro CAS:
36322-90-4
Poids moléculaire :
331.35
Numéro MDL:
MFCD00057317
Code UNSPSC :
41116107
ID de substance PubChem :
329831444
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

piroxicam

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CN1C(C(=O)Nc2ccccn2)=C(O)c3ccccc3S1(=O)=O

InChI

1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)

Clé InChI

QYSPLQLAKJAUJT-UHFFFAOYSA-N

Informations sur le gène

human ... PTGS1(5742) , PTGS2(5743)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Piroxicam for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Cyclooxygenase inhibitor.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1544508

Piroxicam, United States Pharmacopeia (USP) Reference Standard

P2130000

Piroxicam, European Pharmacopoeia (EP) Reference Standard

PHR1588

Piroxicam, Pharmaceutical Secondary Standard; Certified Reference Material

BP463

Piroxicam, British Pharmacopoeia (BP) Reference Standard

1544541

Piroxicam Related Compound D, United States Pharmacopeia (USP) Reference Standard

1544574

Piroxicam Related Compound G, United States Pharmacopeia (USP) Reference Standard

1544600

Piroxicam Related Compound J, United States Pharmacopeia (USP) Reference Standard

1544520

Piroxicam Related Compound B, United States Pharmacopeia (USP) Reference Standard

1544519

2-Aminopyridine, United States Pharmacopeia (USP) Reference Standard

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H301,H373

Classification des risques

Acute Tox. 3 Oral - STOT RE 2 Oral

Organes cibles

Gastrointestinal tract

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Michael A Kron et al.
Clinical and vaccine immunology : CVI, 20(2), 276-281 (2012-12-21)
The therapeutic effects of a controlled parasitic nematode infection on the course of inflammatory bowel disease (IBD) have been demonstrated in both animal and human models. However, the inability of individual well-characterized nematode proteins to recreate these beneficial effects has
Jian X Wu et al.
Journal of pharmaceutical sciences, 102(3), 904-914 (2012-12-06)
Several factors with complex interactions influence the physical stability of solid dispersions, thus highlighting the need for efficient experimental design together with robust and simple multivariate model. Design of Experiments together with ANalysis Of VAriance (ANOVA) model is one of
Xin-Yue Song et al.
Talanta, 100, 153-161 (2012-11-13)
A novel design of carbon nanotubes reinforced hollow fiber solid/liquid phase microextraction (CNTs-HF-SLPME) was developed to determine piroxicam and diclofenac in different real water samples. Functionalized multi-walled carbon nanotubes (MWCNTs) were held in the pores of hollow fiber with sol-gel
Andres Lust et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 48(1-2), 47-54 (2012-10-23)
The aim of this study was to gain understanding about the effects of different solid-state forms of a poorly water-soluble piroxicam on drug dissolution and oral bioavailability in rats. Three different solid-state forms of piroxicam were studied: anhydrate I (AH)
D Gerber
Drug intelligence & clinical pharmacy, 21(9), 707-710 (1987-09-01)
During the approximately five years (1981-86) that piroxicam has been available in South Africa, the Medicines Safety Centre has received 31 reports of adverse reactions associated with this drug. Among these are two reactions not previously recorded in the literature
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique